



Universiteit
Leiden
The Netherlands

DNA damage signaling networks: from stem cells to cancer

Carreras Puigvert, J.

Citation

Carreras Puigvert, J. (2011, October 20). *DNA damage signaling networks: from stem cells to cancer*. Retrieved from <https://hdl.handle.net/1887/17980>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/17980>

Note: To cite this publication please use the final published version (if applicable).

Curriculum Vitae

Jordi Carreras Puigvert was born on the 27th of September 1978 in La Roca del Vallès, Barcelona. In 1997 he completed his secondary education at the Escoles Pies de Nostra Senyora in Barcelona with the speciality of science. In 1999 he completed his education to become a clinical laboratory technician at the Institut Roger de Lauria in Barcelona. He obtained his Master of Science degree in Biotechnology (MSc) at the Universitat Autònoma de Barcelona in 2005. Until 2006 he worked as a HPLC research technician at the faculty of Veterinary at the Universitat Autònoma de Barcelona. And in 2006 he started his new position as a research technician in the lab of Prof. Dr. Bob van de Water, in the Department of Toxicology of the LACDR (Leiden/Amsterdam Centre for Drug Research) in Leiden, The Netherlands. After half a year in the department, in 2007, he started his PhD research program where he investigated the DNA damage response in mouse embryonic stem cells. During this period he developed an automated microscopy technique to follow apoptosis in real time. He also investigated the role of integrins in combination with a cancer background that modulate chemosensitivity. In the last period of his PhD, he carried out several siRNA survival screens to unveil novel components of the DNA damage response in mouse embryonic stem cells. Currently, he works as a Postdoc at the department of Toxicogenetics of the Leiden University Medical Centre in a project aimed to find novel targets for drugs that exploit the DNA damage response.

